摘要
目的对慢性乙型肝炎(CHB)患者进行拉米夫定(LAM)多位点耐药突变检测。方法提取病毒核酸,对聚合酶链反应扩增产物进行测序,采用DNA STAR(Lasergene)软件分析测序结果。结果共对1 704例CHB患者进行耐药突变检测,检出的主要突变类型为rtM204V/I,约占60.1%,约36.1%的患者合并rtL180M突变,1.3%的患者合并rtV173L突变。结论rtM204V/I是LAM耐药突变的主要类型,可合并rtL180M或rtV173L突变;准确检测各类型耐药突变对临床用药具有重要的指导意义。
Objective To test Lamivudine（LAM）-associated multiple drug resistant gene mutation in patients with chronic hepatitis B（CHB）.Methods Virus DNA was amplified by polymerase chain reaction,and the production was sequenced and then analyzed by using DNA STAR（Lasergene） software.Results Total 1 704 cases of patients were detected,among which 60.1% were with rtM204V/I mutation,including 36.1% combined with rtL180M mutation and 1.3% combined with rtV173L mutation.Conclusion The major LAM-associated drug resistant mutation might be rtM204V/I,which could be combined with rtL180M or rtV173L mutation.It might be important to test drug resistant gene mutations for different kinds of anti-virus drugs.
出处
《检验医学与临床》
CAS
2013年第11期1395-1396,共2页
Laboratory Medicine and Clinic
关键词
慢性乙型肝炎
拉米夫定
耐药基因
chronic hepatitis B
Lamivudine
drug resistant gene
